Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Johnson and Johnson
Novartis
Cantor Fitzgerald
Chubb
Baxter
Boehringer Ingelheim
Farmers Insurance
UBS
US Army

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,754,091

« Back to Dashboard

Which drugs does patent 8,754,091 protect, and when does it expire?


Patent 8,754,091 protects IMBRUVICA and is included in one NDA.

This patent has one hundred and twenty patent family members in twenty-six countries.

Summary for Patent: 8,754,091

Title:Inhibitors of bruton's tyrosine kinase
Abstract: Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s): Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee: Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:13/542,440
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pharmacyclics Inc
IMBRUVICA
ibrutinib
CAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,754,091

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,940,750Inhibitors of bruton's tyrosine kinase► Subscribe
8,008,309Inhibitors of bruton's tyrosine kinase► Subscribe
8,975,266Inhibitors of Bruton's tyrosine kinase► Subscribe
8,691,546Inhibitors of Bruton's tyrosine kinase► Subscribe
8,563,563Inhibitors of bruton's tyrosine kinase► Subscribe
8,501,751Inhibitors of Bruton's tyrosine kinase► Subscribe
8,703,780Inhibitors of Bruton's tyrosine kinase► Subscribe
7,514,444Inhibitors of bruton's tyrosine kinase► Subscribe
9,181,257Inhibitors of Bruton's tyrosine kinase► Subscribe
8,232,280Inhibitors of bruton'S tyrosine kinase► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,754,091

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria531263► Subscribe
Australia2006348662► Subscribe
Australia2008232762► Subscribe
Australia2010201052► Subscribe
Australia2012205166► Subscribe
BrazilPI0622054► Subscribe
BrazilPI0622277► Subscribe
BrazilPI0810086► Subscribe
Canada2663116► Subscribe
Canada2681756► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Medtronic
Mallinckrodt
Julphar
Cerilliant
Colorcon
AstraZeneca
Argus Health
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot